Iclusig (ponatinib hydrochloride)
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)
June 2016
WARNINGS AND PRECAUTIONS
Increased Toxicity in Newly Diagnosed Chronic Phase CML
In a prospective randomized clinical...
Source: Drugs.com - Labeling Changes - Category: Drugs & Pharmacology Source Type: alerts